Results: 860 patients with CABP were enrolled from sites in 16 countries, and a microbiological diagnosis (all pathogens) was established in 53.6% of patients. Mpn infection was diagnosed in 9.2% of all enrolled patients. Mpn was detected throughout the year, at overall rates by region ranging from 5.9% in South Africa to 10.9% in Europe. The mean age of Mpn patients was 52.9 (range 18-87), versus 57.6 (18-93) for non-Mpn patients. The mean baseline PSI score for Mpn patients was 68.9 (range 52-102) versus 71.4 (48-112) . 44.3% of patients with Mpn had other CABP pathogen(s) identified. Mpn isolates (N=26) were highly susceptible to solithromycin (MIC 90 0.000032 μg/mL) in comparison with moxifloxacin (MIC 90 0.125 μg/mL). 83.8% of patients treated with solithromycin had an early clinical response versus 78.6% of those treated with moxifloxacin. Clinical success rates at the test of cure visit 5-10 days after treatment were comparable (89.2% vs. 90.5%).
Conclusions:
Mpn is a significant, global etiologic agent of CABP, causing moderate to severe disease in adults of all ages. Mpn pneumonia was effectively treated by solithromycin. -Serum assayed at serial 2-fold dilutions. The final serum dilution (titer) at which characteristic Mpn colonies were observed established baseline or convalescent Mpn 'titer', with appropriate positive and negative controls.
-Serologic diagnosis of Mpn infection required demonstration of a 4-fold or greater increase in acute-to-convalescent IgG serum antibody titer (a convalescent titer of 1:160 was required).
-SP4 transport media was inoculated with oropharyngeal swabs (dacron) and immediately frozen for shipment to the University of Alabama Diagnostic Mycoplasma Lab (Birmingham, AL).
-Culture media inoculated with transport media, and monitored for up to 5 weeks for evidence of Mpn growth, as previously described (Waites 2010).
-M. pneumoniae detected in transport media or positive culture tubes (and differentiated from M. hominis and other commensals) by real-time PCR targeting the M. pneumoniae repMp1 gene as previously described (Dumke 2007).
-Macrolide resistance gene detection performed by multiplex real-time PCR assay, as previously described (Li 2009).
-Solithromycin and moxifloxacin susceptibility testing performed by broth microdilution assay (Waites 2010 (Waites , 2012 CLSI 2011 ).
• M. pneumoniae Culture and PCR Mycoplasma pneumoniae (Mpn), also known as the "Eaton Agent", was first isolated in cell culture in 1944. This bacterium lacks a cell wall (and thus is insensitive to -lactam antibiotics such as ceftriaxone) and is among the smallest free-living organisms with a genome of approximately 816,394 base pairs (Xiao 2015) . Infection with this pathogen, classically referred to as "walking pneumonia", is common, infecting up to 2 million people per year in the US and occurring in epidemic outbreaks in both institutions and across countries. Mpn has been increasingly recognized as a significant cause of CABP, affecting all age groups, with repeated infections well documented (Kannan 2012). However, the very young and elderly patients are at an increased risk for developing serious CABP, with notable morbidity and mortality. Recently, the CDC reported an Mpn outbreak in a Nebraska long-term care facility, which was associated with the death of seven elderly patients (Hastings 2015) . • M. pneumoniae is a significant CABP pathogen, globally.
• M. pneumoniae-specific PCR of oral pharyngeal swab specimens had high concordance with more time consuming culture and IgG serologic responses (data not shown), and is a promising assay for rapid diagnosis.
• M. pneumoniae IgM responses lacked specificity (when compared to culture, PCR, and IgG responses) (data not shown), and
were not used to define Mpn infection for this study.
• The most frequently identified pathogens in order of prevalence were S. pneumoniae (23%), H. influenzae (16%), L. pneumophila (14%), M. pneumoniae (9%), M. catarrhalis (6%), and S. aureus (4%).
• M. pneumoniae was identified in patients from age 18 (the younger limit for enrollment) through 87, and was often associated with high fever, leukocytosis, and CRP elevation. However, up to 1/3 of patients had a normal serum procalcitonin level at baseline.
• M. pneumoniae isolates, including those resistant to azithromycin, were exquisitely susceptible to solithromycin (MIC 90 0.000032 μg/mL).
• Solithromycin and moxifloxacin were associated with comparable and high treatment success rates (89.2% vs 90.5%).
• These data support a treatment strategy that includes empiric coverage for atypical pathogens in the treatment of CABP. 
